• nimble
  • bold
  • focused
  • driven
  • creative
Loading

Medcura

Series B Equity Offering

Medcura presents a compelling investment opportunity in the rapidly growing global hemostasis market, which is ripe for technological disruption. The company has developed a novel biopolymer platform that has received the first and only FDA Breakthrough Device Designation for a surgical hemostat, addressing the critical need for non-swelling solutions in delicate surgical procedures. Medcura’s flagship product, LifeGel, is poised to revolutionize the $2.8 billion global hemostasis market by offering a unique combination of high safety, efficacy, and cost-effectiveness.

COMPANY HIGHLIGHTS:

Market Opportunity: Medcura’s portfolio targets approximately 85% of the $2.8 billion global hemostasis market, with a particular focus on the $600 million global spine hemostasis segment

Innovative Technology: Proprietary biopolymer platform leverages advanced chemistry to create customized performance, addressing longstanding issues such as swelling and high costs

Regulatory Progress: Five 510(k) clearances and two FDA Breakthrough Device Designations demonstrate differentiation, regulatory de-risking and potential for accelerated approval pathways

Margin Potential: With substantially lower cost of goods, LifeGel offers significantly higher profitability compared to thrombin-based competitors’ margins

Intellectual Property: Extensive patent protection in the U.S. and EU, coupled with years of product design and process know-how, creates significant barriers to entry

Experienced Management: Accomplished team with a track record of successful product development, regulatory approvals and large exits in the medical device industry

Financial Projections: Medcura projects LifeGel launching in 2027, growing from $14 million in Year 1 to $90 million by Year 3 and $200 million in Year 5, driven by adoption in both ambulatory spinal surgery centers & hospitals.  These forecasts do not include upside use of LifeGel elsewhere in surgery or revenues from other platform form factors

Exit Potential: The surgical hemostasis space has seen consistent M&A activity as acquisitions are a key strategy for incumbents to defend market dominance and expand product lines